CYP2C9 genotypes and the pharmacokinetics of tenoxicam in Brazilians

Clinical Pharmacology and Therapeutics
R Vianna-JorgeGuilherme Suarez-Kurtz

Abstract

Cytochrome P450 (CYP) 2C9, the product of the polymorphic gene CYP2C9, provides the major catabolic pathway for several anti-inflammatory drugs, including tenoxicam. Our objectives were (1) to determine the frequency of 2 common CYP2C9 variant alleles (*2 and *3) in the Brazilian population and (2) to evaluate the effects of these polymorphisms on the pharmacokinetics of tenoxicam. Polymerase chain reaction-restriction fragment length polymorphism methods were used to identify CYP2C9*2 and CYP2C9*3 in 331 healthy Brazilians, classified as white (n = 136), black (n = 77), or intermediate (n = 118). A validated HPLC procedure was used for measuring the plasma concentrations of tenoxicam, after single oral doses of 20 mg, administered to 21 individuals with CYP2C9*1/*1 (n = 12), CYP2C9*1/*2 (n = 4), or CYP2C9*1/*3 genotypes (n = 5), confirmed by deoxyribonucleic acid sequencing. A 2-compartment pharmacokinetic model was used for fitting the plasma concentration versus time data, and the individual model descriptive parameters were used to simulate the plasma tenoxicam concentrations during repeated dosing for 7 consecutive days. The frequencies of CYP2C9*1, CYP2C9*2, and CYP2C9*3 in the study population were 0.849, 0.086, and 0.06...Continue Reading

Citations

Apr 22, 2009·The Pharmacogenomics Journal·Paula Sánchez-DizAdolfo Figueiras
Oct 10, 2012·The Pharmacogenomics Journal·J E WyattS Harirforoosh
Apr 2, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Vikas KumarTimothy S Tracy
Dec 9, 2004·Pharmacogenomics·Gianfranco FerraccioliBarbara Tolusso
Jul 4, 2008·Pharmacogenomics·Victoria RollasonJules Desmeules
May 14, 2010·Future Cardiology·Richard L SeipGualberto Ruaño
May 28, 2010·Pharmacogenomics·Ulrike M StamerFrank Stüber
Nov 23, 2012·Pharmacogenomics·Pedro DoradoUNKNOWN CEIBA.FP Consortium of the Ibero-American Network of Pharmacogenetics and Pharmacogenomics RIBEF
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Mar 8, 2005·Drug Metabolism Reviews·Haiping HaoJianguo Sun
Jun 15, 2013·Mediators of Inflammation·Svatopluk SvětlíkOndřej Slanař
Aug 30, 2008·Clinical Pharmacology and Therapeutics·J A PeriniG Suarez-Kurtz
May 26, 2016·Brazilian Oral Research·Adriana Maria CalvoCarlos Ferreira Santos
Jan 14, 2017·Journal of Clinical Pharmacology·Francine Attié de CastroVera Lucia Lanchote
Nov 10, 2004·The Pharmacogenomics Journal·G M VasconcelosG Suarez-Kurtz
Oct 24, 2007·European Journal of Clinical Pharmacology·M V LimaR Vianna-Jorge
Mar 13, 2009·Archives of Pharmacal Research·Jung-Woo BaeSeok-Yong Lee
Oct 13, 2011·The Journal of Pharmacy and Pharmacology·Arjun Muralidharan, Maree T Smith
Jul 30, 2019·Journal of Clinical Pharmacology·Estela Hanauer SchaabEduardo Barbosa Coelho
Sep 14, 2006·Pharmacological Reviews·Sharon J Gardiner, Evan J Begg
Mar 19, 2020·Expert Opinion on Drug Metabolism & Toxicology·Yolanda MacíasJosé A G Agúndez
Oct 15, 2014·Molecular Diagnosis & Therapy·Vanessa Cristina de Oliveira AlmeidaAna Lúcia Brunialti Godard
Aug 25, 2005·Drug Metabolism and Disposition : the Biological Fate of Chemicals·A David Rodrigues
Feb 4, 2011·Cancer Chemotherapy and Pharmacology·Bruno José Dumêt FernandesVera Lucia Lanchote
May 4, 2011·Arquivos de neuro-psiquiatria·Carlos Alexandre TwardowschyCarlos Eduardo Silvado
Dec 1, 2004·Personalized Medicine·Julia KirchheinerJürgen Brockmöller
Aug 20, 2020·Revista latino-americana de enfermagem·Jordana Carvalhaes de MoraesRiccardo Lacchini
Aug 7, 2012·Journal of Cellular and Molecular Medicine·Anca D BuzoianuSorin Crişan
Mar 1, 2013·European Journal of Drug Metabolism and Pharmacokinetics·Ekta VarshneyShakir Ali
Nov 21, 2012·Drug Metabolism and Pharmacokinetics·Takeshi HirotaIchiro Ieiri
Nov 19, 2020·European Journal of Clinical Pharmacology·Giovana M WeckwerthCarlos F Santos
Oct 7, 2006·Farmacia hospitalaria : órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria·C MartínezJ A G Agúndez
Jul 10, 2010·Thrombosis Research·Fernanda A OrsiKaren E Weck

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.